Skip to main content


Health

"There is concern that with a license for multiple sclerosis, the cost of alemtuzumab could rise and might become too expensive for many patients and health systems," an editorial in the medical journal the Lancet warns.
809 of 1792




Newsletter Sign Up



Daily Readings

Gospel, John 11:19-27
and many Jews had come to Martha and Mary to comfort them about ... Read More

Saint of the Day

July 29 Saint of the Day

St. Martha
July 29: "Jesus loved Martha and Mary and Lazarus." This unique ... Read More